Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation
Antoine Thierry(Université de Poitiers), G. Touchard(Centre Hospitalier Universitaire de Poitiers), R. Abou Ayache(Centre Hospitalier Universitaire de Poitiers), François Guilhot(Centre Hospitalier Universitaire de Poitiers), Frank Bridoux(Université de Poitiers), Serge Milin(Université de Poitiers), Brian Dreyfus(Centre Hospitalier Universitaire de Poitiers)
Cited by 11
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
|Blood|2012|543
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520